Exploiting translation inhibition: antitumor efficacy of SVC112 in preclinical models of colorectal cancer

被引：0

作者：

Robertson, Kelli M. ^{[1
]}

Gustafson, Annika L. ^{[1
]}

Tentler, John J. ^{[1
]}

Bagby, Stacey M. ^{[1
]}

Anna, Capasso ^{[1
]}

Klauck, Peter J. ^{[1
]}

Pitts, Todd M. ^{[1
]}

Kim, Jihye ^{[1
]}

Tan, Aik Choon ^{[1
]}

Su, Tin Tin ^{[2
]}

Eckhardt, S. Gail ^{[1
]}

机构：

[1] Univ Colorado, Sch Med, Denver, CO USA

[2] Univ Colorado, Denver, CO 80202 USA

来源：

MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期

关键词：

D O I：

10.1158/1535-7163.TARG-17-B051

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

B051

引用

页数：2

共 50 条

[21] Akt inhibition improves the efficacy of cabazitaxel nanomedicine in preclinical taxane-resistant cancer models
Li, Tongyu
Chen, Xiaona
Wan, Jianqin
Hu, Xiaoxiao
Chen, Wanzhi
Wang, Hangxiang
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2021, 607
[22] CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer
Devapatla, Bharat
Sharma, Ankur
Woo, Sukyung
PLOS ONE, 2015, 10 (09):
[23] Met target inhibition-guided efficacy in preclinical models
Srivastava, Apurva K.
Hollingshead, Melinda G.
Govindharajulu, Jeevan P.
Covey, Joseph M.
Liston, Dane
Peggins, James
Bottaro, Donald P.
Wright, John J.
Kinders, Robert J.
Tomaszewski, Joseph E.
Doroshow, James H.
Parchment, Ralph E.
CANCER RESEARCH, 2014, 74 (19)
[24] Estimating Preclinical Efficacy Targets Utilizing Cetuximab Efficacy in KRAS Mutant and Wild-type Colorectal Cancer Models
Prewett, Marie
Bassi, Rajiv
Paz, Keren
Amatulli, Michael
Deevi, Dhanvanthri
Li, Huiling
Wang, Su
Witte, Larry
Samakoglu, Selda
Tonra, James R.
ANTICANCER RESEARCH, 2011, 31 (06) : 2149 - 2160
[25] Antitumor efficacy of a liposomal formulation of irinotecan in preclinical gastric cancer models: Augmenting its response by antiangiogenic agents
Awasthi, Niranjan
Schwarz, Margaret A.
Zhang, Changhua
Klinz, Stephan
Meyer-Losic, Florence
Beaufils, Benjamin
Thiagalingam, Arunthathi
Schwarz, Roderich E.
CANCER RESEARCH, 2020, 80 (16)
[26] Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer
Marshall, Derek C.
Lyman, Susan K.
McCauley, Scott
Kovalenko, Maria
Spangler, Rhyannon
Liu, Chian
Lee, Michael
O'Sullivan, Christopher
Barry-Hamilton, Vivian
Ghermazien, Haben
Mikels-Vigdal, Amanda
Garcia, Carlos A.
Jorgensen, Brett
Velayo, Arleene C.
Wang, Ruth
Adamkewicz, Joanne I.
Smith, Victoria
PLOS ONE, 2015, 10 (05):
[27] Targeting MYC in colorectal cancer by inhibition of translation initiation
Wiegering, A.
Uthe, F.
Germer, C. -T
Eilers, M.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 157 - 157
[28] Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer
Peter J. Klauck
Stacey M. Bagby
Anna Capasso
Erica L. Bradshaw-Pierce
Heather M. Selby
Anna Spreafico
John J. Tentler
Aik Choon Tan
Jihye Kim
John J. Arcaroli
Alicia Purkey
Wells A. Messersmith
Keisuke Kuida
S. Gail Eckhardt
Todd M. Pitts
BMC Cancer, 18
[29] An antibody–drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer
Joan Jacob
Liezl E. Francisco
Treena Chatterjee
Zhengdong Liang
Shraddha Subramanian
Qingyun J. Liu
Julie H. Rowe
Kendra S. Carmon
British Journal of Cancer, 2023, 128 (8) : 1592 - 1602
[30] Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer
Klauck, Peter J.
Bagby, Stacey M.
Capasso, Anna
Bradshaw-Pierce, Erica L.
Selby, Heather M.
Spreafico, Anna
Tentler, John J.
Tan, Aik Choon
Kim, Jihye
Arcaroli, John J.
Purkey, Alicia
Messersmith, Wells A.
Kuida, Keisuke
Eckhardt, S. Gail
Pitts, Todd M.
BMC CANCER, 2018, 18

← 1 2 3 4 5 →